These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Maple syrup urine disease (branched-chain keto-aciduria) variant type manifesting as hyperkinetic behaviour and mental retardation. Report of two cases. Kalyanaraman K; Chamukuttan S; Arjundas G; Gajanan N; Ramamurthi B J Neurol Sci; 1972 Feb; 15(2):209-17. PubMed ID: 5010106 [No Abstract] [Full Text] [Related]
7. Tailoring of the diet for the individual in maple syrup urine disease: long-term home dietary treatment of an adult patient with MSUD by monitoring of daily intake with a personal computer. A case report. Lie IE; Haugstad S; Holm H Hum Nutr Appl Nutr; 1985 Apr; 39(2):130-6. PubMed ID: 3839494 [TBL] [Abstract][Full Text] [Related]
8. [Intermittent maple syrup urine disease in a 12-year-old boy: clinical aspects, diagnosis and treatment]. Fritsch G; Langenbeck U; Wendel U; Lehnert W; Palm W; Steger W Klin Padiatr; 1983; 195(5):351-4. PubMed ID: 6632715 [TBL] [Abstract][Full Text] [Related]
9. Mild variant of maple syrup urine disease. Kovács J; Kiss P Acta Paediatr Acad Sci Hung; 1978; 19(2):137-43. PubMed ID: 707084 [TBL] [Abstract][Full Text] [Related]
10. [Mild variant of maple syrup disease]. Kovács J Orv Hetil; 1978 Nov; 119(47):2889-92. PubMed ID: 714440 [No Abstract] [Full Text] [Related]
11. Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease. Schadewaldt P; Hammen HW; Ott AC; Wendel U J Inherit Metab Dis; 1999 Aug; 22(6):706-22. PubMed ID: 10472531 [TBL] [Abstract][Full Text] [Related]
12. Intermediate maple syrup urine disease: neuroimaging observations in 3 patients from South India. Bindu PS; Shehanaz KE; Christopher R; Pal PK; Ravishankar S J Child Neurol; 2007 Jul; 22(7):911-3. PubMed ID: 17715290 [TBL] [Abstract][Full Text] [Related]
13. Exfoliative erythroderma resulting from inadequate intake of branched-chain amino acids in infants with maple syrup urine disease. Northrup H; Sigman ES; Hebert AA Arch Dermatol; 1993 Mar; 129(3):384-5. PubMed ID: 8447687 [No Abstract] [Full Text] [Related]
14. [Biochemical studies in a patient with maple syrup urine disease (author's transl)]. Vaca G; Rivas F; Sánchez-Corona J; Olivares N; Aguirre-Negrete MG; González-Quiroga G; Medina C; Hernández A; Cantú JM Rev Invest Clin; 1981; 33(4):379-82. PubMed ID: 7330511 [No Abstract] [Full Text] [Related]
15. Detection of maple syrup urine disease on resin coated chromatosheets. Kovács J Acta Biochim Biophys Acad Sci Hung; 1979; 14(3):119-21. PubMed ID: 547666 [No Abstract] [Full Text] [Related]
16. [Dietary treatment of maple syrup urine diseases]. Guibaud P; de Parscau L; Guffon N; Laval MC Pediatrie; 1993; 48(10):681-6. PubMed ID: 8015866 [TBL] [Abstract][Full Text] [Related]
17. Elevated excretion of N-acetylated branched-chain amino acids in maple syrup urine disease. Lehnert W; Werle E Clin Chim Acta; 1988 Feb; 172(1):123-6. PubMed ID: 3359650 [No Abstract] [Full Text] [Related]
18. M aple syrup urine disease. A review with a report of an additional case. Schwartz JF; Kolendrianos ET Dev Med Child Neurol; 1969 Aug; 11(4):460-70. PubMed ID: 5805351 [No Abstract] [Full Text] [Related]
19. Branched-chain alpha-keto acids for the diagnosis of maple-syrup-urine disease. Parsons H; Fung E; Snyder FF N Engl J Med; 1987 Apr; 316(15):951. PubMed ID: 3821846 [No Abstract] [Full Text] [Related]
20. Urinary biomarkers of oxidative damage in Maple syrup urine disease: the L-carnitine role. Guerreiro G; Mescka CP; Sitta A; Donida B; Marchetti D; Hammerschmidt T; Faverzani J; Coelho Dde M; Wajner M; Dutra-Filho CS; Vargas CR Int J Dev Neurosci; 2015 May; 42():10-4. PubMed ID: 25680940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]